Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: how important is internal dosimetry?

  • Christoph Trauernicht Stellenbosch University
  • Pieter Du Toit

Abstract

The South African Association of Physicists in Medicine and Biology (SAAPMB) and the associated South African Medical Physics Society (SAMPS) would like to congratulate the College of Nuclear Physicians on the publication of the practice guidelines on Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumours.1 Unfortunately these guidelines might create the impression that the associated internal dosimetry assessment is just an optional extra, with only a single short paragraph on post-therapy images that are obtained to confirm uptake of therapy agents in the tumour and for dosimetry assessment. This is in stark contrast to the joint IAEA, EANM and SNMMI guidance document,2 which has a whole section on dosimetry. Radiation dosimetry of normal organs and malignant lesions allows the dose to the tumour to be maximised, while keeping the dose to normal tissues low enough to reduce the risk of delayed organ toxicity.

Author Biographies

Christoph Trauernicht, Stellenbosch University

Division of Medical Physics, Department Medical Imaging and Clinical Oncology, Faculty of Health Sciences, Stellenbosch University

Pieter Du Toit

Chairperson of SAMPS, Private Practice

Published
2018-11-26
How to Cite
Trauernicht, C., & Du Toit, P. (2018). Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: how important is internal dosimetry?. South African Journal of Surgery, 57(1), 57. Retrieved from http://sajs.redbricklibrary.com/index.php/sajs/article/view/2960
Section
Letters to the Editor